NASDAQ:AMIX Autonomix Medical Q2 2027 Earnings Results & Report $1.82 +0.13 (+7.35%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Autonomix Medical beat analyst earnings expectations in its Q2 2027 results, released November 10, 2026. The company reported EPS of -$2.51 versus the -$2.62 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2027Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Autonomix Medical EPS ResultsActual EPS-$2.51Consensus EPS -$2.62Beat/MissBeat by +$0.11One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersAutonomix Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Autonomix Medical Q2 2027 Earnings FAQ Did Autonomix Medical beat earnings estimates for Q2 2027? Autonomix Medical (NASDAQ:AMIX) reported earnings of -$2.51 per share for Q2 2027, beating the consensus estimate of -$2.62. The report was announced on Tuesday, November 10, 2026. Autonomix Medical Earnings HeadlinesAutonomix Medical (AMIX) Expected to Announce Quarterly Earnings on WednesdayNovember 10 at 3:11 AM | americanbankingnews.comAutonomix Medical consensus price target lowered by 30.61% to $41.62October 22, 2026 | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Autonomix Medical, Inc. (AMIX) Receives a Buy from Maxim GroupOctober 18, 2026 | theglobeandmail.comAutonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural ValidationOctober 2, 2026 | globenewswire.comAutonomix Medical Completes FDA Pre-Submission Meeting On Standalone Transvascular Sensing PlatformSeptember 30, 2026 | rttnews.comSee More Autonomix Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Autonomix Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autonomix Medical and other key companies, straight to your email. Email Address About Autonomix MedicalAutonomix Medical (NASDAQ:AMIX) is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures. Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures. The platform may also have applications in other conditions involving abnormal nerve activity, including certain cardiovascular and neurological disorders. The company is headquartered in The Woodlands, Texas, and its technology remains in the development and clinical evaluation stage. Autonomix Medical’s common stock trades on the Nasdaq Capital Market under the symbol AMIX.View Autonomix Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
